Most patients who survive a stroke experience some degree of physical recovery. Selecting the appropriate outcome measure to assess physical recovery is a difficult task, given the heterogeneity of stroke etiology, symptoms, severity, and even recovery itself. Despite these complexities, a number of strategies can facilitate the selection of functional outcome measures in stroke clinical trial research and practice. Clinical relevance in stroke outcome measures can be optimized by incorporating a framework of health and disability, such as the International Classification of Functioning, Disability, and Health (ICF). The ICF provides the conceptual basis for measurement and policy formulations for disability and health assessment. All outcome measures selected should also have sound psychometric properties. The essential psychometric properties are reliability, validity, responsiveness, sensibility, and established minimal clinically important difference. It is also important to establish the purpose of the measurement (discriminative, predictive, or evaluative) and to determine whether the purpose of the study is to evaluate the efficacy or effectiveness of an intervention. In addition, when selecting outcome measures and time of assessment, the natural history of stroke and stroke severity must be regarded. Finally, methods for acquiring data must also be considered. We present a comprehensive overview of the issues in selecting stroke outcome measures and characterize existing measures relative to these issues.
INTRODUCTION
Stroke is a leading cause of disability in the United States. 1 Regardless of the initial severity of the disability and neurological deficit, most stroke survivors exhibit some degree of recovery over time. [2] [3] [4] [5] Assessment of recovery in individuals after stroke is important for both clinical practice and research, 6 but selecting outcome measures is a difficult process. Outcome measurement in stroke is difficult due to the various etiologies of stroke, heterogeneity of symptoms, variability in severity, and the possibility of spontaneous recovery after stroke. 7 Despite such complexities, several strategies can facilitate the selection of functional outcome measures in stroke clinical trial research and practice.
Clinical relevance in stroke outcome measures can be optimized by incorporating a framework of health and disability. The International Classification of Functioning, Disability and Health (ICF) is the World Health Organization framework for health and disability. The ICF provides the conceptual basis for measurement and policy formulations for disability and health. According to the ICF model, outcomes may be measured at the following levels: body functions and structure (impairment), activities, and participation. Activities and participation are affected by environmental and personal factors. 8 All outcome measures selected should also have sound psychometric properties. The essential psychometric properties are reliability, validity, responsiveness to change, sensibility, 7 and minimal clinically important difference (MCID). Reliability of an outcome measure refers to the extent to which a score is free of random error 9 ; validity is the capacity of an instrument to measure what it is intended and presumed to measure 10 ; responsiveness to change is the ability of an outcome measure to detect clinically important changes 7 ; sensibility refers to the overall appropriateness, importance, and ease of use of the instrument [2] [3] [4] [5] ; and the MCID helps to define a threshold that is considered to be an important improvement. [11] [12] [13] Generic outcome measures are useful for comparisons across populations and with normal age and gendered values. Condition-specific measures are more suitable for assessments within a specific client group. Whether the measure has been used within the stroke population is an important characteristic of an outcome measure, and it should be regarded as a relative indicator of how well the instrument might function within a given sample of individuals who have experienced stroke. 7, 14 Another essential factor in selecting outcome measures is to establish the purpose of the measurement. The purposes of outcome measures could be discriminative, predictive, or evaluative. Discriminative studies are designed to separate patients into discrete classes that can be defined according to specific diagnostic criteria. In predictive studies, patients are classified into groups against a known criterion or gold standard. Evaluative studies are intended to reflect clinically important changes. 15 When selecting outcome measures use and timing of use, the natural history of stroke and stroke severity must be considered. Recovery after stroke is strongly influenced by time since onset and by baseline stroke severity. Individuals with stroke usually experience some degree of recovery. 16 More than 80% of patients with mild stroke reach maximum improvement in activities of daily living (ADL) function within 3 weeks, and thus the assessment of only ADL in this subgroup of individuals with stroke is insufficient to capture the full extent of stroke impact according to the ICF model. 16 These individuals may continue to have limitations in physical function, instrumental activities of daily living (IADL), and participation. Thus, a more global emphasis is needed in poststroke assessment for those with mild stroke. Patients with more severe stroke may not achieve independence in ADL, and in that population ADL assessment, as well as assessment of the other domains, is appropriate. 17 The outcome measures selected for clinical trials may differ depending on whether the study is efficacy-oriented or effectiveness-oriented. The goal of efficacy trials is to optimize the chance of detecting a biological effect with as few patients as possible. 18, 19 Because impairment scales may be the most sensitive to change and have the greatest capacity to differentiate between treatment groups, they are particularly useful for efficacy studies. 20 The aim of effectiveness trials is to determine whether interventions have beneficial results when they are administrated in the context of ordinary clinical practice. 21 Studies that focus on effectiveness are broadly conceptualized and are assessed not only for primary outcomes but also for a wide range of outcomes relevant to public health, such as comorbidity, quality of life, and cost effectiveness. 22, 23 It is also important for researchers and clinicians to understand the different methods of acquiring data. The main data acquisition methods consist of self-administered questionnaires, interviewer-administered interviews, or observational assessments, along with varying models including telephone-administered, face-to-face, or computerized/web-based methods. The assessments can be performed with the patient or with a proxy, such as a family member or health care provider.
The purpose of this article is to provide a comprehensive overview of the issues in selecting stroke outcome measures and to characterize existing measures relative to these issues.
CONCEPTUAL FRAMEWORK
The ICF provides a conceptual framework for selection and classification of outcome measures. 24 -26 Outcomes may be measured at any of these levels:
1. Body functions or structure (impairment): problems in body function or structure as a significant deviation or loss.
poststroke disability assessment should comprise the impairment domains of motor weakness, sensory and propri- oceptive deficits, and cognition impairments. 29 As impairment scales may be the most sensitive to change and have the greatest capacity to differentiate between treatment groups, they are particularly useful for efficacy studies. 20 However, for clinical significance and health policy it is important to relate changes in impairments to changes in activity and participation.
Activity
Activities measures are the most frequently used primary outcome measures in stroke. The most common domain of activity measurement is basic ADLs. However, in an unselected stroke population, approximately 60% of the patients will make a "complete recovery" in basic ADL. 8 Thus, measures of ADLs may have a ceiling effect and may not show a difference between groups in outcome, significantly reducing the power of any study. 28 For example, most patients with mild stroke spontaneously achieve independence in ADLs early, and therefore, make it difficult to detect an intervention effect on ADL. Thus, ADLs measures, such as the Barthel Index, will have a ceiling effect in stroke patients with mild deficits and other significant limitations may not be captured (e.g., important improvements in higher level functions such as household maintenance, shopping and quality-of-life status). Therefore, researchers need to stratify patients into different degrees of initial severity. 7 In the minor and moderate stroke strata the benchmarks of recovery must include measures of higher level of activity (i.e., IADLs) or mobility since they may be more sensitive to differences between groups 28,30 and they do not suffer from ceiling effect. 28 In the severe stroke patients' strata, assessment of recovery of basic ADLs and mobility may be an appropriate primary outcome measure. 17 A challenge in all activity and mobility measures is that the link between the extent of loss at the level of pathology and impairment is not perfectly correlated and other factors may influence the outcome. 7, 31 For example, an individual may improve in motor function, but without good social support to encourage independence, he or she may not become more independent in ADL, IADL, or participation.
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Participation
Although legislation, reports, and classification schemes promote the concept of participation as an important component of disability, the development of measures capturing the essence of participation has just begun. 33 One possible reason for the delay in development is that tasks subsumed within the participation level are relatively complex, more dependent on environmental influences and on social support, and usually assessed in the community by self or proxy report. 25 The concept of quality of life is reflected in both participation and activity. However, quality of life is defined differently in quality of life models than in ICF activity and participation. In quality of life models, quality of life involves several core dimensions, including physical functioning, emotional well-being, social functioning, and role activities, as well as health perceptions and global assessment of life satisfaction. 34 The ICF defines activity as the execution of a task or action by an individual, and participation as the involvement in a life situation. 27 Depression is another factor influencing stroke recovery. Depression may be considered an impairment that strongly influences activity and participation. It should always be considered for measurement in clinical practice and research, because symptoms occur in about one-third of poststroke patients. 35 Depending on the purpose of the study, depression may be considered as a primary outcome or a modifier of the relationship between impairment, activity and participation. There are established measures of depression that have been validated for stroke patients (e.g., Geriatric Depression Scale, 36 Beck Depression Inventory, 37 and Center for Epidemiologic Studies Depression). 38 Depression assessments should be taken from the patient rather than a proxy.
Environmental factors will also have an impact on activity and participation and are organized in sequence from the individual's most immediate environment to the general environment. 27 The family is one example of an important environmental factor. Indeed, it has been demonstrated that early involvement of the family unit is strongly correlated with patient adherence to therapy, better understanding between patient and caregiver of achievable outcomes, and improved communication between patient and caregivers. 39 Thus, the family or social support may be a modifier that needs to be considered for clinical research.
Measurement of recovery at just one level gives only a partial picture of the recovery process. For example, many ADLs can be performed despite the presence of significant impairments. If only the level of activity is monitored, the patterns of neurological recovery may be disguised. Measuring stroke recovery at the impairment, activity, and participation levels allows the determination of the impact of changes in impairments on changes in activity and perceived quality of life. 7 International experts identified the categories that account for the fundamental and most striking aspects of stroke related functioning. They created the Brief ICF Core Set. 40 The categories included in the brief ICF core set are given in TABLE 1. In TABLE 2 we have drawn on the work of Salter et al., 24 -26 Duncan et al., 41 and Gresham et al. 42 to present an annotated list of the most commonly used instruments of stroke trials and clinical practice, classified by ICF categories of impairment, activities, and environmental factors.
OUTCOME MEASURES' PSYCHOMETRIC PROPERTIES
Psychometric properties are critical to the selection of any outcome measure. The essential psychometric properties are reliability, validity, responsiveness, and sensibility. 7 Whether the measure has been used within the stroke population and whether it has an established MCID are also important characteristics of outcome measures.
Reliability
Reliability of an outcome measure refers to the extent to which a score is free of random error. A score on an outcome measure is composed of two parts: true variance and measurement variance. True variance captures the variability in the attribute of interest. Measurement variance is random error and represents variability due to other factors. Measurement variance may be due to a variety of factors, including fatigue, cognitive factors, and mode of test administration. 9 Reliability is defined as the proportion of the score that contains information about the attribute of interest as opposed to measurement error. It is expressed as a coefficient from 0 to 1, with 1 representing perfect reliability. 7 There are three basic ways to evaluate the reliability of a given instrument: internal consistency, interrater reliability, and test-retest reliability Internal consistency reliability. Internal consistency reliability is the most frequently used estimate of the reliability of a measure. A measure of internal consistency is the average degree of association among the items on a test. 43 To compute internal consistency, a single version of an instrument is administered to a single group of test subjects at a single time point. The data are then analyzed for consistency. 44 According to Andresen, 45 excellent internal consistency is reported at Ն0.80, adequate is 0.70 -0.79, and poor is Ͻ0.70.
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Interrater reliability. Interrater reliability concerns variation between two or more raters who measure the same group of subjects. 46 Many potential threats to interrater reliability exist in any test situation. For instance, Blackburn et al. 47 evaluated the reliability of measurements obtained with the Modified Ashworth Scale in the lower extremities of people with stroke. They reported poor levels of interrater reliability, despite use of written guidelines. In their study, the assessors had not been trained specifically in the use of the scale, suggesting that Stroke Specific Quality of life [24] [25] [26] EuroQoL-5D [24] [25] [26] Stroke Impact Scale [24] [25] [26] 41 Sickness Impact Profile (stroke-adapted version) [24] [25] [26] 41, 42 Family Family assessment device 41, 42 40 guidelines need to be accompanied by training of test administrators to achieve improved reliability. 47 Generally, 80% agreement between raters is the minimum required.
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Test-retest reliability. Test-retest reliability is the correlation between scores obtained by the same person on two separate occasions. The interpretation is complicated by the fact that actual changes may have occurred in behavior or functional status during the time interval itself. Thus, low test-retest reliability does not necessarily reflect the psychometric properties of the test. 43 Excellent test-retest reliability is Ն0.75, adequate is 0.4 -0.74, and poor is Յ0.40.
24 -26 Fitzpatrick et al.
14 recommend a minimum test-retest reliability of 0.90 if the measure is to be used to evaluate the ongoing progress of an individual in a treatment situation. Testretest reliability of measures is often established in chronic stroke subjects who are not continuing to experience recovery.
Validity
Demonstrating reliability in measurement is essentially providing the existence of a stable or generalizable concept; however, reliability says nothing about the nature of the concept. Thus, a set of items may yield a repeatable score, but one that may be an invalid indicator of the construct under study. 48 Validity is the capacity of an instrument to measure what it is intended to and presumed to measure. Many types of validity are referred to in the literature, such as face, content, discriminative, convergent, predictive, and criterion. 10 Of these, the most important are criterion and predictive validity. 7 Criterion validity refers to the performance of the instrument against an external gold standard or the actual outcome that the test was developed to assess. 43 Predictive validity is a form of criterion validity 24 -26 and is the degree to which a test can predict how well an individual will do in a future situation.
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Responsiveness
Responsiveness is sensitivity to changes within patients over time, which may be indicative of therapeutic effects. 24 -26 Responsiveness is most commonly evaluated through correlation with other scores, effect sizes, standardized response means, relative efficiency and sensitivity and specificity of change scores. For example, when examining sensitivity to change in an expected direction, the standardized effect method categorizes Ͻ0.5 as small, 0.5-0.8 as moderate, and Ն0.8 as large. 24 -26 Assessment of possible floor and ceiling effects is included, because they indicate limits to the range of detectable change beyond which no further improvement or deterioration can be noted. 24 -26 Such effects can seriously damage the capacity of a trial to detect change. If patients achieve the top score on a major outcome scale at baseline, no improvement can be detected. Conversely, if patients start out at the bottom of a scale, no deterioration can be measured. 7 There are adequate floor and ceiling effects when Յ20% of patients attain either the minimum (floor) or maximum (ceiling) score. 24 -26 Several investigators have examined the sensitivity of common outcome measures used in stroke rehabilitation. For example, English et al. 49 investigated the sensitivity of gait speed, the Berg Balance Scale, and the Motor Assessment Scale. Gait speed and the Berg Balance Scale were both sensitive to change and demonstrated large effect sizes. The Motor Assessment Scale item five (walking) also showed a large effect size and was able to detect change among lower functioning subjects. The effect sizes of the other items of the Motor Assessment Scale were small, and the majority of subjects showed no change over time on these measures. Houlden et al. 50 compared the responsiveness of the Barthel Index and the Functional Independence Measure (FIM). They concluded that the Barthel Index and the total and physical FIM scores showed similar responsiveness, and that the cognitive FIM score was least responsive. These findings suggest that none of the FIM scores have any advantages over the Barthel Index. 50 For additional examples of stroke outcome measure sensitivity studies published in the past few years, please refer to Wallace et al. 51 and Hsueh et al.
52
Sensibility Sensibility refers to the overall appropriateness, importance, and ease of use of an instrument; it is a major factor determining the success or failure of a clinical measure. The primary consideration in choosing an outcome measure is the correspondence between the dimensions of the measure (impairment, activity, or participation) and the goals of the intervention and the study. 7 For example, if the goal of the intervention is to improve upper extremity motor recovery, select measures that reflect upper extremity motor function. In addition, the measures that are selected must not be burdensome for the patient, yet should capture the range of their abilities. 7 Has the measure been used within the stroke population?
An important factor to consider when evaluating outcome measures' psychometric properties is whether or not the measure has previously been used within the stroke population. Reliability and validity are not fixed qualities of measures. They should be regarded as relative indicators of how well the instrument might function within a given sample or for a given purpose. 14, 53 Sensitivity to change may likewise be condition-or purposespecific. 24 -26 For example, as previously mentioned, the Barthel Index has a ceiling effect in stroke patients with mild deficits, yet it may be one of the most sensitive measures in patients with more severe impairments. 7 It is important for a measure to have been tested for use in the population within which it will be used.
-26
MCID and the concept of sliding dichotomy
In the presence of a plethora of available instruments and evidence of their psychometric properties, outcomes research is currently faced with the challenge of interpretability 54 of the scores. When health status is measured, it is worth knowing whether an observed difference indicates a clinically significant or trivial effect on the patient's health status or quality of life. A statistically significant difference in health status or quality of life measures might be of little clinical or practical importance; it is more important to know the MCID. 55 Pursuit of the MCID is one important area of current work in interpretability. 11 Jaeschke 55 first defined an MCID as being "the smallest difference in score in the domain of interest which patients perceive as beneficial." Since then, the definition has varied. Looking only at articles published in the past few years, we see definitions such as "the smallest difference in a score that is considered to be worthwhile or important." 12, 56 Several stakeholders would share an interest in determining the MCID. Researchers would use this for sample size determination, drug companies need this for interpreting the results of trials, and clinicians could use this to guide clinical care.
11
The use of continuous scales versus ordinal scales is an important consideration in the calculation of clinically significant results. When the outcome measure is continuous, such as gait velocity, it is important to determine whether the measure has a meaningful change or an absolute change, by establishing a MCID. When outcome measures are ordinal, however, they must generally be converted according to severity as a dichotomous outcome of "favorable" or "unfavorable," in order to determine clinical relevance; that is, a cutoff score must be established to demarcate a positive or negative test. 57 For example, the Berg Balance Scale can be used to predict if a stroke patient is at risk for falling. A cutoff score of Ͻ45 is typically used to indicate that an individual may be at grater risk for falling. 58 Thus, a score of Ն45 is considered to be a "favorable" outcome, and a score of Ͻ45 is an "unfavorable" outcome.
However, an instrument that defines function dichotomously as "favorable" versus "unfavorable" does not accord with every day clinical practice 59 and may be too coarse to detect smaller degrees of MCID. 7 The concept of sliding dichotomy is a novel approach that answers both of the major objections to the conventional dichotomous analysis. The idea is that, instead of taking a single definition of "good" outcome for all patients, the definition is tailored to each individual patient's baseline prognosis on entry to the trial. 59 For a patient with a very severe injury, independence in basic ADLs alone might be regarded as a good outcome. For a patient with a mild injury, however, only a return to community participation would be regarded as a good outcome. 59 In practice, the approach would be implemented by grouping patients into a number of bands according to their baseline prognosis. Each band would have a customized dichotomy of the outcome scale to differentiate between "good" and "bad" outcome. The total number of good outcomes in the intervention group would be compared with the corresponding number of good outcomes in the control group. 59 (For further information about the concept of sliding dichotomy, see Murray et al. 59 ) Characteristics of the most commonly used stroke outcome measures relative to the psychometric properties described above are presented in the Appendix. MCID is one of the psychometric properties evaluated. Unfortunately, this psychometric property has not been evaluated in the majority of the most common stroke outcome measures. Nonetheless, establishment of MCID is critical in designing effectiveness studies or in clinical trials that will influence clinical decision making and health policy.
PURPOSE OF MEASUREMENT
There are three purposes of measurement: discriminative, predictive, and evaluative. 15 Each of these three purposes of measurement scale has a useful role to play in rehabilitation, but mismatching the types can result in incorrect assessment information.
43
Discriminative scales
Discriminative scales are used to distinguish between individuals or groups with respect to underlying dimension when no external criterion or gold standard is available for validating these measures. 60 These scales are used in between-subjects experimental designs that use separate samples for each treatment condition. 61 Thus, if one had two groups of patients with stroke and wanted to examine the differences between the two groups in ADLs, one would require a discriminative scale.
Predictive scales
Predictive scales are used to classify individuals into a set of predefined measurement categories when a gold standard is available. This gold standard is subsequently used to determine whether individuals have been classified correctly. Let us assume that investigators had developed a mobility instrument that took Ͼ1 hour to administer. Because an hour represents a rather long test, it would be desirable to have a shorter version. One might choose a subsample from the original test and examine the performance of the new, shorter instrument using the original as a gold standard. 60 
Evaluative scales
Evaluative scales are used to measure the magnitude of longitudinal change in an individual or group 60 (within subjects experimental design). Within-subjects experimental designs are experiments in which two sets of data are obtained from the same sample. They compare treatment effects by looking at changes in performance within each participant across treatments. 61 Thus, for an evaluative scale, we might ask whether a particular change in a patient's ADL score represents a trivial, small but important, moderate, or large improvement or deterioration. 62 In summary, the distinction in type of measurement adds a third dimension to the conceptual framework. The 3-dimensional model of functional assessment was described by Turner 43 and its terms and constructs were updated by the authors. Along one axis are the three areas of assessment: impairment, activity, and participation. Along the second axis are the domains of assessment that are generally accepted as relevant for rehabilitation outcomes as well as in health status assessment. Along the third axis are the types of measurement. The modified 3-dimensional model of functional assessment is presented in FIG. 2 . This model can be used to guide the questions the user needs to ask at the onset of the assessment task: What is the appropriate unit of analysis? How many, and which content domains are relevant? What is my assessment goal? Answers to these questions should help identify a preliminary set of outcome measures instruments, which can then be examined more closely for evidence of psychometric quality. 43 
NATURAL HISTORY OF STROKE AND STROKE SEVERITY
When considering the use of an outcome measure or the time of assessment, natural history of stroke and stroke severity should be considered.
Approximately 25% of patients worsen during the first 24 hours following stroke. 63 Beyond that first period, however, individuals with stroke usually experience some degree of recovery. Recovery is the most dramatic during the first 30 days after a stroke. 16, 64, 65 By the end of the first 3 months, patients who survive stroke almost always have less physical disability. Thus, measurements of activities (e.g., the Barthel Index and FIM) tend to show a plateau of gains by 3 months after stroke, partly owing to insensitivity of the scale to further improvements. 66 However, based on initial stroke severity there are different trajectories of recovery. For example, in more severe strokes recovery may be more protracted (FIG. 3) . 67 
Efficacy and effectiveness trials
As we select outcome measures for interventions, it is particularly important to understand the distinction between efficacy-oriented and effectiveness-oriented clinical trials.
Efficacy trials. The focus of efficacy trials is usually a newly developed intervention or a promising modification of a well established one. 21 Whatever the investigative issue, the intention is to conduct a well-controlled experiment under ideal conditions, using relative homogeneous samples. 18, 21 The goal of efficacy trials is to optimize the chance of detecting a biological effect with as few patients as possible. 18, 19 Because impairment scales may be the most sensitive to change and have the greatest capacity to differentiate between treatment groups, they are particularly useful for efficacy studies. 20 Thus, the study endpoint will most likely reflect the impairment the treatment is attempting to minimize. 20 For example, if the intervention goal is to improve upper extremity motor function, then the measure selected will be Fugl-Meyer upper extremity, and researchers and clinicians should not expect major changes in mobility assessments. Finally, the duration of follow-up for clinical endpoints (functional outcome) does not need to exceed 3 months in typical efficacy studies; shorter periods may be possible. A shorter time period will likely reduce variation in clinical outcome due to subsequent events unrelated to the study.
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Effectiveness trials. The aim of effectiveness trials is to determine whether interventions have beneficial results when they are administrated in the context of ordinary clinical practice. As such, effectiveness trials are principally concerned with the external validity of treatment outcomes. 21 Studies that focus on effectiveness are broadly conceptualized, use heterogeneous samples that are recruited in a variety of practice settings, and are assessed not only for primary outcomes but also for a wide range of outcomes relevant to public health, such as comorbidity, quality of life, and cost effectiveness. 22, 23 In addition, participants tend to be followed for a longer duration, and data analysis can place greater emphasis on differences among subgroups. Features such as these just listed may indeed enhance the generalizability of a study, but they may also introduce possible confounds that allow the results to be attributed to factors other than the intervention itself. 21 In effectiveness studies, the most clinically relevant outcome must be assessed. For the most part, these will include activities and participation measures. The most commonly used outcome measure in effectiveness studies have been the Barthel Index and the Rankin or modified Rankin scale 17 ; however, the Barthel Index is known to be insensitive to small changes in functional status and to have significant ceiling effects. The Rankin scale has been criticized as inherently insensitive and for mixing objective and subjective items, which span impairment, activity, and participation aspects of recovery. 28 Given the limitations of the Barthel Index and Rankin Scale, the new Stroke Impact Scale (SIS) has been increasingly endorsed in effectiveness trials. The SIS has been developed to be a more comprehensive measure of health outcomes for stroke populations. The SIS incorporates meaningful dimensions of function and health-related quality of life into one self-report questionnaire. The SIS version 3 includes 59 items and assesses eight domains (strength, hand function, ADL and IADL, mobility, communication, emotion, memory and thinking, and participation or role function).
66
Methods of acquiring data
Another important issue in selecting outcome measures is methods of acquiring data.
When assessment requires a form of self-report, several modes of assessment exist: trained interviewers vs. selfadministered, administration by a healthcare professional or other proxy, and computerized adaptive test (CAT).
Trained interviewers versus self-administered. Questionnaires are either administered by trained interviewers or self-administered. Although having trained interviewers is resource intensive, it both ensures compliance and minimizes errors and missing items. The self-administered 
FIG. 3.
The trajectory of Barthel ADL recovery for stroke patients with different levels of initial stroke severity. Subjects are stratified for severity using the Orpington Prognostic Scale. In the Barthel Index, a score of 0 represents complete inability and a score of 100 represents complete ability on all items. Adapted from the Kansas City Stroke Study, unpublished data (data collection started in October 1995 and was completed in 1999).
approach is much less expensive, but increases the number of missing patients and missing responses. A compromise between the two approaches is to have the instrument completed under supervision. Another compromise is the telephone interview, which minimizes errors and missing data but dictates a relatively simple questionnaire structure.
60
Proxy and healthcare professional's report. Impairment and activity measures can be performance-based, but participation and quality of life are most often selfreported. 24 -26 Self-report measures are limited, however, by the cognition and communication problems of stroke survivors. 68 For example, in a large study that used mailadministered quality of life questionnaires, 50% of the stroke subjects were unable to complete the questionnaires by themselves. 69 Moreover, study results can be seriously compromised and misleading if subjects who are suffering from severe deficits are excluded. The inclusion of proxy data will increase sample size, improve generalizability, and reduce sample bias. 70 Nonetheless, the use of proxy respondents should be approached with caution. 24 -26 Proxy assessors tend to assess patients as more disabled than they appear on other measures of functional disability, including self-reported methods. This discrepancy becomes more pronounced for patients with more impaired levels of functioning. [71] [72] [73] This discrepancy could be explained by a difference in interpretation. Proxy respondents may be rating actual, observable performance, whereas patients may rate their perceived capability-what they think they are capable of doing, rather than what they actually do. 72 Unfortunately, a similar discrepancy has been noted in ratings when using healthcare professionals as proxy respondents, although in the opposite direction. Healthcare professionals may tend to rate patients higher than the patients themselves would. 73, 74 Again, the discrepancy may be due to a difference in frame of reference. A healthcare professional may use a more disabled group as reference norm, whereas patients would simply compare themselves to prestroke conditions. 74 Clinicians and researchers also need to pay attention to measurement consistency. If researchers and clinicians use proxy respondents at the beginning of the intervention ("pre-test") they should be consistent and use the proxy respondents throughout the study or intervention ("post-test").
Data acquisition has typically relied on traditional, fixedlength tests, which tend to be long and require administering items that are high (or even too high) for those with low trait values and items that are low (or too low) for those with high trait values. 75 However, do all items need to be administered to every person? Can we get an accurate estimate of function if we administer fewer items, and do so without sacrificing precision? Can individual assessment be personalized by drawing from a large item-pool, based on that person's responses? The use of CAT methodology with a large item-pool is the new assessment frontier, and it may provide an effective solution to these measurement challenges.
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CAT. Computerized adaptive testing has been applied in educational and psychological testing for decades, 76 and it is currently being used to administer the Graduate Record Examination. Only recently has CAT technology been applied to rehabilitation and health service research. 77 Unlike fixed-length paper-and-pencil tests, CAT tests provide different test-item sets for each examinee based on that person's estimated trait (or ability) level. 78 An adaptive test first asks questions in the middle of the ability range, and then, based on the responses, asks subsequent questions that focus on relevant functional levels. Thus, precise information regarding an individual's functional ability level is obtained, with fewer items administered, 76 and the information about each individual can be assessed most efficiently. 78 CAT is ideally suited to item response theory (IRT) methods. 79 IRT makes it possible to estimate an individual's trait levels with any subset of items in an item pool. Methods based on IRT overcome the limitations of ordinal data, provide detailed examination of item performance and respondent validity, and control for rater severity. 80 IRT methods have been widely used in the field of education 81 ; in rehabilitation, they have been used to psychometrically assess the FIM. 82 The simplest of the IRT models, the Rasch model, represents the essential elements for developing measures that are both efficient and precise. 83 The Rasch model breaks down assessing an individual into its most basic elements, person ability minus item difficulty. In using this formula to determine a person's ability level, the most information about an individual is obtained when person ability matches item difficulty or when the individual has a 50% probability of passing or being successful on an item. 84 Thus, it is unnecessary to administer all test items to every person. For example, if a person has a 50% probability of being successful at standing without any assistance device, it would be imprudent to ask that individual a very easy task (e.g., to sit down on a chair) or a very complex task (e.g., to run upstairs).
SUMMARY
Clinical investigators and clinicians are increasingly concerned with the selection of appropriate outcome measures, because these measures will have an impact on detecting treatment effects. There is no general consensus, however, on the battery of measures that should be used in clinical stroke trials and clinical practices. Thus, to improve the selection of stroke outcome measures, we offer for consideration the following recommendations:
1. Clinical relevance in stroke outcome measures can be optimized by incorporating the framework of Health and Disability, the ICF. This model will help establish the domains of outcome measures.
2. All outcome measures should have established psychometric properties (e.g., reliability, validity, and sensitivity to change) and should have been tested in individuals with stroke.
3. The purpose of measurement should guide researchers and clinicians in identifiable areas of function that should be assessed (e.g., impairment, ADL, IADL).
4. The natural history of stroke and stroke severity must be considered when outcome measures are selected.
5. The type of study (efficacy versus effectiveness studies) should also dictate the type of outcome measures selected.
6. The mode of administration has to be taken into consideration (e.g., phone, interview, or self-report). Yes. 24, 91, 92 Extensively evaluated measure, good validity and reliability for assessing sensorimotor function and balance. 41, 42 Considered too complex and timeconsuming by many 41, 42 ; examines synergy patterns that no longer form the basis for many functionally oriented treatments. 91 Modified Ashworth
APPENDIX
Testing should be relatively brief. 24 Adequate. 24 Poor. 24 Insufficient data. 24 Not established. Yes. 93, 94 Has widespread clinical acceptance, is routinely used to assess spasticity, is the current clinical standard. 95 Some questions remain whether the scale is a valid measure of spasticity 96 ; no standardized testing procedures or guidelines for the use of the scale exist, reliability of the test is dependent upon the muscle being assessed. 94 
Neurobehavioral
Cognition Status Exam (NCSE)
10-20 min. 97 The NCSE had good test-retest reliability ( ϭ 0.69), but the inter-rater reliability was not as good ( ϭ 0.57).
98
Has well demonstrated validity. 97, 99 Sensitive to cognitive effects of stroke, although there was little discrimination between leftsided and right sided strokes.
100
Patients who have scores that are lower than those in the average range on any test are impaired in that specific skill. Yes. 97, [99] [100] [101] Predicts gain in Barthel Index scores, unrelated to age. 41, 42 Does not distinguish right from left hemisphere, no reliability studies in stroke, correlates with education 41, 42 ; visual and motor problems make completion of block design difficult. 101 
Mini Mental
State Examination 10 min. 41, 42 Excellent. 24 Adequate. 24 Insufficient data. 24 A score of Յ23 is the generally accepted cutoff point indicating presence of cognitive impairment. 102 Levels of impairment have also been classified as none (24) (25) (26) (27) (28) (29) (30) ; mild (18) (19) (20) (21) (22) (23) (24) , and severe (0-17). 103 Yes. 104, 105 Widely used for screening. 41, 42 Brief. 106 Several functions with summed score, heavily language dependent, likely to misclassify patients with aphasia. 41, 42 Yes. 130 Simple, well established with stroke patients, sensitive to change. 41, 42 May suffer from decreased sensitivity in early stages post stroke among severely affected patients.
131
Timed Up-andGo A few minutes 26 Excellent. 26 Adequate. 26 Insufficient data. 26 Cutoff score for high risk for falls in communitydwelling older adults is Ն14 s to complete the test. 132 According to Shumway-Cook, 133 adults without neurological impairments who are independent with balance and mobility skills are able to perform the Timed Up-and-Go test in Ͻ10 s.
Yes. 134 Quick, easy to administer, can be accomplished in community, timed scores are objective, requires no specialized equipment and training. 135 May not be suitable for use among individuals exhibiting cognitive impairment 136 ; addresses relatively few aspects of balance. 135, 137 10 Meter walk A few minutes High. 138 Validity established in many studies. 138 Sensitive measure of recovery of post-stroke mobility. Yes. 138, 140 Simple, related to the severity of impairment in the home and the community 139 ; less likely to show a ceiling effect. 141 A variation in gait speed of Յ25% limits the tests reliability 142 ; the 10-m walk test does not provide a continuous-scale assessment of gait recovery following stroke. Early during rehabilitation phase, patients may not be able to walk 5-10 m, and are therefore not testable (floor effect) 143 ; as patients improve, walking speed Ͼ5-10 m becomes a less credible measure of walking speed over more functionally relevant distances outside the home. 143 ; quick and easy to implement and can be completed by many patients. 147 Cannot assess other important aspects of gait such as quality of movement, balance, use of assist devices, and amount of physical assistance needed.
143
The 6-min walk is usually described as a measure of endurance, fatigability, and cardiovascular fitness, 148 but there are a number of strokespecific impairments that could potentially alter the outcome of the test-for example, factors such as muscle weakness, balance impairment, and spasticity might influence the distance walked. 149 Wolf High. 152 High concurrent validity.
152,153
Item 5 (walking) showed a large effect size; the other items have small effect sizes (d ϭ 0.36-0.5) and the majority of subjects showed no change over time. 49 Not reported. Yes. 49, 152, 153 Brief assessment of movement and physical mobility 41, 42 ; good reliability and validity. 106 Reliability assessed only in stable patients. 41, 42 Rivermead Motor Assessment Յ40 min. 26 Adequate. 26 Adequate. 26 Poor. 26 Collin and Wade 142 propose that a total score difference of Ϯ3 may represent a clinically relevant change.
Yes (stroke specific). 26 The time spent making the assessment is directly related to the patient's level of motor functioning 154 ; can be self-reported. 138 Time consuming 142 ; the validity of the scale as a Guttman scale is questionable. 26 Motricity Index (MI) 5 min. 41, 42 Good. 138 Good. 138 Sensitivity not tested. 41, 42 Based on clinical experience, Kwakkel et al. 155 considered MI arm score of Ն11, and MI leg score of Ն25 to be associated with good outcome of upper extremity dexterity at 6 mo after stroke.
Yes. 138 Brief and simple assessment of motor function of arm, leg, and trunk. 41, 42, 138 Sensitivity not tested. Adequate. 25 Adequate. 25 Insufficient data. 25 Patients with a total score of Ͼ33 have poor health profiles.
172
Yes (stroke specific). 25 Comprehensive and well evaluated, broad range of items reduces floor or ceiling effects 41, 42 ; no special equipment or training is required. 25 Time to administer somewhat long; evaluates behavior rather than subjective health 41, 42 ; does not assess pain, recreation, energy, general health perceptions, overall quality of life, or stroke symptoms. 173 Family assessment device 30 min. 41, 42 Excellent. 41, 42 Excellent 41, 42 Not tested. Cutoff score Ͼ 2.0 indicates unhealthy family. 174 No stroke specific studies found.
Widely used in stroke, computer scoring available, excellent validity and reliability, available in multiple languages. 41, 42 Assessment subjective; sensitivity not tested; ceiling and floor effects. 41, 42 * The RCI statistic determines the magnitude of change score necessary for a given self-report measure to be considered statistically reliable. Note that the RCI alone does not indicate clinical significance. By itself, the RCI expresses only the amount of change between pre-and post-treatment scores on the SF-36 that would be statistically reliable. The SF-36 RCIs reported are relatively large, meaning that fairly substantial change scores in the SF-36 scales are needed for clinical significance. This is due in large part to variability in the size of reliability coefficients among the SF-36 scales. In general, the lower the reliability coefficient of a given SF-36 scale, the larger the RCI. 165 
